Natus Medical Incorporated (BABY) Director Sells $154,748.00 in Stock
Natus Medical Incorporated (NASDAQ:BABY) Director Robert A. Gunst sold 4,400 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $35.17, for a total transaction of $154,748.00. Following the transaction, the director now owns 50,850 shares of the company’s stock, valued at approximately $1,788,394.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Natus Medical Incorporated (NASDAQ:BABY) traded down 1.40% during mid-day trading on Friday, hitting $35.10. 310,860 shares of the stock traded hands. The firm’s 50-day moving average is $33.97 and its 200-day moving average is $36.12. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of 60.83 and a beta of 0.96. Natus Medical Incorporated has a 52 week low of $31.65 and a 52 week high of $44.39.
Natus Medical (NASDAQ:BABY) last announced its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.01. The company had revenue of $122.20 million during the quarter, compared to the consensus estimate of $121.99 million. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The firm’s revenue for the quarter was up 27.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.39 earnings per share. On average, analysts forecast that Natus Medical Incorporated will post $1.70 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/15/natus-medical-incorporated-baby-director-sells-154748-00-in-stock.html.
Several analysts have recently commented on BABY shares. Zacks Investment Research raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. BidaskClub downgraded shares of Natus Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $44.50.
Institutional investors have recently made changes to their positions in the stock. Riverhead Capital Management LLC raised its holdings in shares of Natus Medical by 90.9% during the second quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock valued at $107,000 after acquiring an additional 1,364 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in shares of Natus Medical during the first quarter valued at approximately $110,000. Sei Investments Co. raised its holdings in shares of Natus Medical by 29.7% during the second quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock valued at $119,000 after acquiring an additional 728 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Natus Medical by 94.0% during the first quarter. Victory Capital Management Inc. now owns 3,184 shares of the medical equipment provider’s stock valued at $125,000 after acquiring an additional 1,543 shares in the last quarter. Finally, Flinton Capital Management LLC raised its holdings in shares of Natus Medical by 82.0% during the second quarter. Flinton Capital Management LLC now owns 3,774 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 1,700 shares in the last quarter. Institutional investors own 92.65% of the company’s stock.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.